Victoria Moyer, MD
Family Medicine · Kokomo, INNPI 1891776951
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $184,310 of the $187,876 with a category attached, or 98.1%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 86.0% of it on its own, with 20 other manufacturers making up the rest. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $578.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$162K
- Shire North American Group Inc$23K
- Novo Nordisk$712
- AbbVie$497
- Lilly USA, LLC$491
- Pfizer$463
- plus $1K from 15 others
What the payments were for
- Consulting fees$184,31098%
- Travel & lodging$730%
- Food & beverage$3,4932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 85 | $161,558 |
| Shire North American Group Inc | 11 | $22,960 |
| Novo Nordisk | 71 | $712 |
| AbbVie | 42 | $497 |
| Lilly USA, LLC | 26 | $491 |
| Pfizer | 24 | $463 |
| AstraZeneca | 18 | $352 |
| Bayer | 14 | $250 |
| Dexcom, Inc. | 7 | $133 |
| Abbott | 6 | $103 |
| Exact Sciences | 4 | $68 |
| GSK | 4 | $67 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Amgen | 3 | $47 |
| Boehringer Ingelheim | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 2 | $16 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$187,876 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 201 | $275,818 |
| MounjaroTirzepatide | 158 | $205,746 |
| EliquisApixaban | 91 | $114,053 |
| JardianceEmpagliflozin | 83 | $106,236 |
| RybelsusSemaglutide | 42 | $76,836 |
| TrulicityDulaglutide | 43 | $65,489 |
| JanuviaSitagliptin Phosphate | 29 | $45,241 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $35,665 |
| LinzessLinaclotide | 38 | $30,974 |
| XareltoRivaroxaban | 52 | $30,944 |
| FarxigaDapagliflozin Propanediol | 18 | $24,724 |
| VraylarCariprazine Hcl | 15 | $24,386 |
| TrintellixVortioxetine Hydrobromide | 23 | $23,161 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 95 | $20,800 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $16,689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $712 | $352,654243 claims |
| Lilly USA, LLCMounjaro, Trulicity | $491 | $271,234201 claims |
| PfizerEliquis, Abrysvo | $463 | $120,696112 claims |
| Boehringer IngelheimJardiance | $24 | $106,23683 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $67 | $64,646140 claims |
| AbbVieLinzess, Vraylar | $497 | $55,36053 claims |
| AstraZenecaFarxiga, Symbicort | $352 | $28,26432 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $161,558 | $23,16123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Kokomo
- Sheryar SarwarKokomo$22K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.